Qiagen partners with AstraZeneca on diagnostic companion for gefitinib in NSCLC

  • July 28, 2014

Qiagen recently announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with its non–small-cell lung cancer treatment, gefitinib.

The project builds on a framework agreement signed by both companies in 2013 and intends to develop and market a novel Qiagen companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
More»
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today